0001140361-22-007674.txt : 20220303 0001140361-22-007674.hdr.sgml : 20220303 20220303161906 ACCESSION NUMBER: 0001140361-22-007674 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220303 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHEMBIO DIAGNOSTICS, INC. CENTRAL INDEX KEY: 0001092662 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880425691 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35569 FILM NUMBER: 22709030 BUSINESS ADDRESS: STREET 1: 555 WIRELESS BLVD. CITY: HAUPPAUGE STATE: NY ZIP: 11788 BUSINESS PHONE: (631) 924-1135 MAIL ADDRESS: STREET 1: 555 WIRELESS BLVD. CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: Chembio Diagnostics Inc. DATE OF NAME CHANGE: 20040607 FORMER COMPANY: FORMER CONFORMED NAME: TRADING SOLUTIONS COM INC DATE OF NAME CHANGE: 19990805 8-K 1 brhc10034728_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 3, 2022
 
graphic

CHEMBIO DIAGNOSTICS, INC.

Nevada
0-30379
88-0425691
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

555 Wireless Blvd. Hauppauge, NY 11788
(Address of principal executive offices) (Zip code)
 
Registrant’s telephone number, including area code:  (631) 924-1135
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol
  
Name of each exchange on which registered
Common Stock, $0.01 par value
  
CEMI
  
The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.         Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
Item 2.02
Results of Operations and Financial Condition.
 
On March 3, 2022, we issued a press release announcing financial results for the quarter and fiscal year ended December 31, 2021. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8‑K and is incorporated herein by reference.
 
The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of Section 11 or Section 12(a)(2) of the Securities Act of 1933. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this report shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by us whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)
Exhibits.
 
 
Exhibit No.
  
Description
       
   
Press Release of Chembio Diagnostics, Inc., dated March 3, 2022
       
 
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be filed on its behalf by the undersigned hereunto duly authorized.

 
Chembio Diagnostics, Inc.
   
Dated: March 3, 2022
By:
/s/ Richard L. Eberly
   
Chief Executive Officer and President


EX-99.1 2 brhc10034728_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1


Chembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial Results

HAUPPAUGE, NY, March 3, 2022 -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2021.

Recent Highlights

 •
Achieved record quarterly total revenue of $20.6 million and product revenue of $17.4 million in the fourth quarter of 2021, representing growth of 101% and 154%, respectively, compared to the prior year period, including:

o
U.S. product revenue of $3.2 million, representing growth of 268% compared to the prior year period

o
Latin America product revenue of $12.0 million, representing growth of 415% compared to the prior year period

•
Achieved record annual total revenue of $47.8 million and product revenue of $34.7 million for the full year 2021, representing growth of 47% and 40%, respectively, compared to the full year 2020, including:

o
U.S. product revenue of $6.0 million, representing growth of 53% compared to 2020

o
Latin America product revenue of $18.4 million, representing growth of 87% compared to 2020

•
Initiated a Global Competitiveness Program intended to improve profitability by focusing on higher margin business, lowering manufacturing costs, reducing infrastructure costs and reviewing non-core businesses and assets

•
Received ANVISA approval and CE mark for the DPP Respiratory Antigen Panel

•
Submitted an EUA application for new DPP SARS-CoV-2 Antigen Test and a De Novo/510(k) request for the DPP Antigen Test System to the U.S. Food and Drug Administration, completing milestones under the BARDA product development award

•
Strengthened its executive leadership team with the addition of Larry Steenvoorden as Chief Financial Officer

“In the fourth quarter, record quarterly revenue was driven by execution of the largest purchase order in company history, received from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil, while navigating the tight labor market and global supply chain issues for certain test components to ramp production. Chembio also finished the year with record annual revenue,” said Richard Eberly, Chembio’s President and Chief Executive Officer. “We are confident our investments in developing products in high value growing markets and registering existing products in additional geographies can drive sustained growth over the long-term. We are optimistic about our ability to improve profitability through continued product revenue growth and reduction of our cost infrastructure beginning in 2022.”

Fourth Quarter 2021 Financial Results
Total revenue for the fourth quarter of 2021 was $20.6 million, an increase of 101% compared to the prior year period. Net product sales for the fourth quarter of 2021 were $17.4 million, an increase of 154% compared to the prior year period. Government grant, license and royalty, and R&D revenue for the fourth quarter of 2021 totaled $3.2 million, a decrease of 6% compared to the prior year period.

Gross product margin for the fourth quarter of 2021 was ($1.6) million, compared to $0.5 million for the prior year period. Gross product margin percentage for the fourth quarter of 2021 was negative 9%, compared to 7% for the prior year period. Gross product margin in the fourth quarter of 2021 was impacted by an unfavorable mix of average selling prices, increased labor costs, and an inventory write down of $2.5 million.

Research and development expenses increased by $0.1 million, or 2%, in the fourth quarter of 2021 compared to the prior year period. Selling, general and administrative expenses decreased by $0.3 million, or 10%, in the fourth quarter of 2021 compared to the prior year period.

Impairment, restructuring, severance and related costs for the fourth quarter of 2021 totaled $4.6 million, including an impairment of goodwill and intangible assets from prior acquisitions.

Net loss for the fourth quarter of 2021 was $14.0 million, or $0.47 per diluted share, compared to a net loss of $7.1 million, or $0.35 per diluted share, for the prior year period. The net loss includes severance, restructuring, an impairment of goodwill and intangible assets from prior acquisitions and other related costs of $4.6 million, or $0.15 per share, for the fourth quarter of 2021, compared to a de minimis amount in the prior year period.

Full Year 2021 Financial Results
Total revenue for 2021 was $47.8 million, an increase of 47% compared to 2020. Net product sales for 2021 were $34.7 million, an increase of 40% compared to 2020. Government grant, license and royalty, and R&D revenue for 2021 totaled $13.1 million, an increase of 70% compared to 2020.

Gross product margin for 2021 was $0.2 million, compared to $0.9 million in 2020. Gross product margin percentage for 2021 was 1%, compared to 4% for 2020. Gross product margin in 2021 was adversely impacted by an unfavorable mix of average selling prices, increased labor costs, and a fourth quarter inventory write down of $2.5 million.

Research and development expenses increased by $3.0 million, or 31%, in 2021 compared to 2020. The increase in research and development expenses was primarily associated with increased clinical trial costs related to the product development award from BARDA. Selling, general and administrative expenses increased by $3.8 million, or 18%, in 2021 compared to 2020. The increase in selling, general and administrative expenses primarily reflected increased legal costs, recruiting fees and higher insurance costs.

Impairment, restructuring, severance and related costs including an impairment of goodwill and intangible assets from prior acquisitions totaled $7.0 million in 2021 compared to $1.1 million in 2020.

Net loss for 2021 was $33.9 million, or $1.40 per diluted share, compared to a net loss of $25.5 million, or $1.34 per diluted share, for 2020. The increase in loss per share was negatively impacted by Impairment, restructuring, severance and related costs including an impairment of goodwill and intangible assets from prior acquisitions.

Cash and cash equivalents as of December 31, 2021 totaled $28.8 million.

Going Concern Considerations
Revenues during the twelve months ended December 31, 2021 did not meet the Company’s expectations. The Company’s increase in cash and cash equivalents over the year reflected our issuance of common stock in at-the-market offerings for net proceeds of $38.8 million. The Company continued to experience market, clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of COVID-19 test systems during the continuing, but evolving, uncertainty of the COVID-19 pandemic. For the year ending December 31, 2021, the Company continued to incur significant expenses in connection with pending legal matters, delayed achievement of milestones associated with government grant income, investments in inventory, and the continuing automation of manufacturing.

The Company performed an assessment to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about our ability to continue as a going concern within one year after the date the audited consolidated financial statemetns will be issued (the “Issuance Date”). Because substantial doubt was determined to exist as the result of this initial assessment, management then assessed the mitigating effect of our plans to determine if it is probable that the plans (1) would be effectively implemented within one year after the Issuance Date and (2) when implemented, would mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern.

During the twelve months ended December 31, 2021, the Company undertook measures to increase our total revenues and improve its liquidity position. These measures included:


 •
On July 19, 2021, the Company entered into an At the Market Offering Agreement (“ATM Agreement”) with Craig Hallum Capital Group LLC (“Craig Hallum”) pursuant to which we may sell from time to time, at our option, up to an aggregate of $60,000,000 of shares of common stock. As of December 31, 2021, the Company has issued and sold pursuant to the ATM Agreement a total of 9,709,328 shares of common stock at a volume-weighted average price of $4.20 per share for gross proceeds of $40.8 million and net proceeds, after giving effect to placement fees and other transaction costs, of $38.8 million.

•
The Company also received significant purchase orders from two customers (the “July Purchase Orders”). The Company had pursued the July Purchase Orders for an extended period of time. The July Purchase Orders consist of the following:

o
On July 20, 2021, the Company received a $28.3 million purchase order from Bio-Manguinhos for the purchase of DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the needs of Brazil’s Ministry of Health in addressing the COVID-19 pandemic. As of December 31, 2021 $16.8 million was recognized in connection with this order.

o
On July 22, 2021, the Company received a $4.0 million purchase order from the Partnership for Supply Chain Management, supported by The Global Fund, for the purchase of HIV 1/2 STAT-PAK Assays for shipment to Ethiopia into early 2022. As of December 31, 2021 $1.2 million was recognized in connection with this order.

These measures and other plans and initiatives have been designed to provide the Company with adequate liquidity to meet its obligations for at least the twelve-month period following the Issuance Date. The Company’s execution of those measures and its other plans and initiatives continue to depend, however, on factors that are beyond the Company’s control, or that may not be addressable on terms acceptable to the Company or at all. The Company has considered in particular how:

 •
The ongoing healthcare and economic impacts of the COVID-19 pandemic on the global customer base for the Company’s non COVID-19 products continue to negatively affect the timing and rate of recovery of its revenues from those products by, for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect the Company’s liquidity.

•
Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products.

The Company further considered how these factors and uncertainties could impact its ability over the next year to meet the obligations specified in the Credit Agreement and Guaranty (the “Credit Agreement”), that the Company and certain of its subsidiaries, as guarantors, entered into with Perceptive Credit Holdings II, LP, (the “Lender”). Those obligations include (a) covenants requiring i) minimum cash balance of $3 million and ii) minimum total revenue amounts for the twelve months preceding each quarter end. For the next year, the minimum total revenue requirements range from $42.0 million for the twelve months ending March 31, 2022 to $47.4  million for the twelve months ending December 31, 2022 and (b) an obligation requiring the payment of principal installments, commencing with the payment of $300,000 on September 30, 2022. Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that the Company would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement or that, if such liquidity were not available, the Company would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern. The Company’s inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for its operations, could have a material adverse effect on the Company’s business, prospects, results of operations, liquidity and financial condition.
Accordingly, management determined the Company could not be certain that our plans and initiatives would be effectively implemented within one year after the Issuance Date. Without giving effect to the prospect of raising additional capital pursuant to the Company’s at-the-market offerings, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond the Company’s control, it is unlikely that the Company will be able to generate sufficient cash flows to meet our required financial obligations, including the Company’s debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the Issuance Date.

Conference Call
Chembio will host a conference call today beginning at 4:30 pm ET to discuss its financial results and recent business highlights. Investors interested in listening to the call may do so by dialing 888-506-0062 from the United States or 973-528-0011 from outside the United States and providing entry code 516973. To listen to a live webcast of the call, please visit the Investor Relations section of Chembio's website at www.chembio.com. Following the call, a replay will be available on the Investor Relations section of Chembio’s website. A telephone replay will be available until 4:30 pm ET on March 17, 2022 by dialing 877-481-4010 from the United States or 919-882-2331 from outside the United States and using passcode 44503.

About Chembio Diagnostics
Chembio is a leading diagnostics company focused on developing and commercializing point-of-care tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
 
Forward-Looking Statements
Certain statements contained in the paragraph following the bulleted items under “Recent Highlights” above are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Chembio’s R&D investments, development of certain products and registration of existing products in new geographies. Such statements, which are expectations only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events or performance may differ materially from forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the following, any of which could be exacerbated even further by the continuing COVID-19 outbreak in the United States and globally: the ability of Chembio to continue to generate revenue from the July Purchase Orders or other product orders, and the margins it can realize from that revenue, or its ability to develop new products, will depend on the availability and cost of human, material and other resources required to build and deliver the tests, which factors are largely outside Chembio’s control; the ability of Chembio to maintain existing, and timely obtain additional, regulatory approvals, which approvals are subject to processes that can change recurringly without notice; the highly competitive and rapidly developing diagnostics market, which includes a number of competing companies with strong relationships with current and potential customers, including governmental authorities, and with significantly greater financial and other resources that are available to Chembio; and the risks of doing business with foreign governmental entities, including geopolitical, international and other challenges as well as potential material adverse effects of tariffs and other changes in U.S. trade policy. Chembio undertakes no obligation to publicly update forward-looking statements in this release to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to the forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's periodic public filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, its Current Report on Form 8-K filed with the Securities and Exchange Commisson on July 19, 2021, and its Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2021 and September 30, 2021, particularly under the heading “Risk Factors.”

DPP is Chembio’s registered trademark, and the Chembio logo is Chembio’s trademark. For convenience, these trademarks appear in this release without ® or ™ symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademarks. All other trademarks appearing in this release are the property of their respective owners.

Investor Relations Contact
Philip Taylor
Gilmartin Group
(415) 937-5406
investor@chembio.com
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

   
For the three months ended
(Unaudited)
    
For the year ended
  
   
Dec. 31, 2021
    
Dec. 31, 2020
    
Dec. 31, 2021
    
Dec. 31, 2020
  
REVENUES:
                        
Net product sales
  
$
17,410,240
    
$
6,852,526
    
$
34,737,444
    
$
24,767,149
  
R&D
    
51,573
      
1,095,402
      
1,159,381
      
4,851,562
  
Government grant income
    
2,861,726
      
2,018,924
      
10,891,726
      
2,018,924
  
License and royalty revenue
    
250,000
      
260,112
      
1,029,901
      
832,562
  
TOTAL REVENUES
    
20,573,539
      
10,226,964
      
47,818,452
      
32,470,197
  
                                 
COSTS AND EXPENSES:
                                
Cost of product sales
    
19,004,846
      
6,361,480
      
34,495,802
      
23,874,487
  
Research and development expenses
    
3,385,061
      
3,275,455
      
12,487,424
      
9,508,494
  
Selling, general and administrative expenses
    
6,806,863
      
7,134,593
      
24,840,611
      
21,037,701
  
Impairment, restructuring, severance and related costs
    
4,606,796
      
-
      
7,047,779
      
1,122,310
  
Acquisition costs
    
-
      
-
      
-
      
63,497
  
     
33,803,566
      
16,771,528
      
78,871,616
      
55,606,489
  
LOSS FROM OPERATIONS
    
(13,230,027
)
    
(6,544,564
)
    
(31,053,164
)
    
(23,136,292
)
                                 
OTHER INCOME:
                                
Interest expense, net
    
(737,227
)
    
(731,818
)
    
(2,912,415
)
    
(2,841,830
)
                                 
LOSS BEFORE INCOME TAXES
    
(13,967,254
)
    
(7,276,382
)
    
(33,965,579
)
    
(25,978,122
)
                                 
Income tax benefit (loss)
    
(5,878
)
    
137,198
      
62,050
      
456,794
  
                                 
NET LOSS
  
$
(13,973,132
)
  
$
(7,139,184
)
  
$
(33,903,529
)
  
$
(25,521,328
)
                                 
Basic and diluted loss per share
  
$
(0.47
)
  
$
(0.35
)
  
$
(1.40
)
  
$
(1.34
)
                                 
Weighted average number of shares outstanding, basic and diluted
    
30,049,338
      
20,150,168
      
24,299,465
      
19,085,691
  

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF

   
December 31, 2021
    
December 31, 2020
  
             
- ASSETS -
            
CURRENT ASSETS:
            
Cash and cash equivalents
  
$
28,772,892
    
$
23,066,301
  
Accounts receivable, net of allowance for doubtful accounts of $243,042 and $296,793 as of December 31, 2021 and December 31, 2020, respectively
    
11,441,107
      
3,377,387
  
Inventories, net
    
12,920,451
      
12,516,402
  
Prepaid expenses and other current assets
    
1,710,194
      
778,683
  
TOTAL CURRENT ASSETS
    
54,844,644
      
39,738,773
  
                 
FIXED ASSETS:
                
Property, plant and equipment, net
    
8,556,773
      
8,688,403
  
Finance lease right-of-use asset, net
    
191,870
      
233,134
  
TOTAL FIXED ASSETS, net
    
8,748,643
      
8,921,537
  
                 
OTHER ASSETS:
                
Operating lease right-of-use assets, net
    
5,891,906
      
6,112,632
  
Intangible assets, net
    
-
      
3,645,986
  
Goodwill
    
3,022,787
      
5,963,744
  
Deposits and other assets
    
744,215
      
509,342
  
                 
TOTAL ASSETS
  
$
73,252,195
    
$
64,892,014
  
                 
- LIABILITIES AND STOCKHOLDERS’ EQUITY -
                
CURRENT LIABILITIES:
                
Accounts payable and accrued liabilities
  
$
13,127,993
    
$
10,042,790
  
Deferred revenue
    
-
      
1,606,997
  
Current portion of long term debt
    
1,200,000
      
-
  
Operating lease liabilities
    
886,294
      
642,460
  
Finance lease liabilities
    
68,176
      
58,877
  
TOTAL CURRENT LIABILITIES
    
15,282,463
      
12,351,124
  
                 
OTHER LIABILITIES:
                
Long-term operating lease liabilities
    
5,976,151
      
6,327,143
  
Long-term finance lease liabilities
    
139,678
      
185,239
  
Long-term debt, less current portion, net
    
17,589,003
      
18,182,158
  
Deferred tax liability
    
-
      
69,941
  
TOTAL LIABILITIES
    
38,987,295
      
37,115,605
  
                 
STOCKHOLDERS’ EQUITY:
                
Preferred stock – 10,000,000 shares authorized, none outstanding
    
-
      
-
  
Common stock - $0.01 par value; 100,000,000 shares authorized; 30,101,393 shares and 20,223,498 shares issued at December 31, 2021 and December 31, 2020, respectively
    
301,050
      
202,235
  
Additional paid-in capital
    
165,772,636
      
124,961,514
  
Accumulated deficit
    
(131,009,860
)
    
(97,106,331
)
Treasury stock 48,057 and 41,141 shares at cost as of December 31, 2021 and December 31, 2020, respectively
    
(206,554
)
    
(190,093
)
Accumulated other comprehensive loss
    
(592,372
)
    
(90,916
)
TOTAL STOCKHOLDERS’ EQUITY
    
34,264,900
      
27,776,409
  
                 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
  
$
73,252,195
    
$
64,892,014
  

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED

    
December 31,
2021
      
December 31,
2020
  
   
CASH FLOWS FROM OPERATING ACTIVITIES:
            
Cash received from customers and grants
  
$
38,093,984
    
$
34,736,133
  
Cash paid to suppliers and employees
    
(65,273,967
)
    
(50,238,409
)
Cash paid for operating leases
    
(1,404,532
)
    
(1,139,944
)
Cash paid for finance leases
    
(20,077
)
    
(19,987
)
Interest and taxes, net
    
(2,281,124
)
    
(2,225,031
)
Net cash used in operating activities
    
(30,885,716
)
    
(18,887,238
)
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
                
Acquisition of and deposits on fixed assets
    
(1,824,285
)
    
(3,961,369
)
Patent application costs
    
(33,398
)
    
(205,493
)
Net cash used in investing activities
    
(1,857,683
)
    
(4,166,862
)
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
                
Proceeds from sale of common stock, net
    
38,811,958
      
28,436,740
  
Proceeds from option exercises
    
85,555
      
-
  
Principal payments for finance leases
    
(61,867
)
    
(51,166
)
Payments on note payable
    
-
      
(180,249
)
Stimulus package loan
    
-
      
2,978,315
  
Payment of stimulus package loan
    
-
      
(2,978,315
)
Payments of tax withholdings on stock award
    
(145,225
)
    
(441,723
)
Net cash provided by financing activities
    
38,690,421
      
27,763,602
  
                 
Effect of exchange rate changes on cash
    
(240,431
)
    
85,447
  
INCREASE IN CASH AND CASH EQUIVALENTS
    
5,706,591
      
4,794,949
  
Cash and cash equivalents - beginning of the period
    
23,066,301
      
18,271,352
  
                 
Cash and cash equivalents - end of the period
  
$
28,772,892
    
$
23,066,301
  
                 
RECONCILIATION OF NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
                
                 
Net Loss
  
$
(33,903,529
)
  
$
(25,521,328
)
Adjustments:
                
Depreciation and amortization
    
2,930,976
      
2,697,126
  
Share based compensation
    
2,431,982
      
1,223,171
  
Benefit from deferred tax liability
    
(69,941
)
    
(396,385
)
Provision for doubtful accounts
    
(53,751
)
    
270,193
  
Non-cash inventory changes
    
4,054,701
      
3,543,515
  
Impairment charges
    
5,880,741
      
-
  
Changes in assets and liabilities, net of effects from acquisitions:
                
Accounts receivable
    
(8,009,969
)
    
283,939
  
Inventories
    
(4,458,750
)
    
(6,461,887
)
Prepaid expenses and other current assets
    
(931,510
)
    
(85,670
)
Deposits and other assets
    
(234,874
)
    
34,195
  
Accounts payable and accrued liabilities
    
3,085,205
      
4,043,896
  
Deferred revenue
    
(1,606,997
)
    
1,481,997
  
Net cash used in operating activities
  
$
(30,885,716
)
  
$
(18,887,238
)
                 
Supplemental disclosures for non-cash investing and financing activities:
                
Deposits on manufacturing equipment transferred to fixed assets
  
$
-
    
$
472,651
  
Contingent liability earnout
    
-
      
1,011,261
  


EX-101.SCH 3 cemi-20220303.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cemi-20220303_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 cemi-20220303_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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image00002.jpg begin 644 image00002.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Mar. 03, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 03, 2022
Entity Registrant Name CHEMBIO DIAGNOSTICS, INC.
Entity Incorporation, State or Country Code NV
Entity File Number 0-30379
Entity Tax Identification Number 88-0425691
Entity Address, Address Line One 555 Wireless Blvd
Entity Address, City or Town Hauppauge
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11788
City Area Code 631
Local Phone Number 924-1135
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001092662
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol CEMI
Security Exchange Name NASDAQ
XML 9 brhc10034728_8k_htm.xml IDEA: XBRL DOCUMENT 0001092662 2022-03-03 2022-03-03 false NY 0001092662 8-K 2022-03-03 CHEMBIO DIAGNOSTICS, INC. NV 0-30379 88-0425691 555 Wireless Blvd Hauppauge 11788 631 924-1135 false false false false Common Stock, $0.01 par value CEMI NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://chembio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10034728_8k.htm brhc10034728_ex99-1.htm cemi-20220303.xsd cemi-20220303_lab.xml cemi-20220303_pre.xml image0.jpg http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10034728_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10034728_8k.htm" ] }, "labelLink": { "local": [ "cemi-20220303_lab.xml" ] }, "presentationLink": { "local": [ "cemi-20220303_pre.xml" ] }, "schema": { "local": [ "cemi-20220303.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cemi", "nsuri": "http://chembio.com/20220303", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10034728_8k.htm", "contextRef": "c20220303to20220303", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://chembio.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10034728_8k.htm", "contextRef": "c20220303to20220303", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001140361-22-007674-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-007674-xbrl.zip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end